Arvinas Inc

ARVN

NASDAQ. Currency in USD

34.31 -1.73 ( -4.80% )

Real time prices: December 19

Market Cap.
1.83B
Beta (5Y monthly)
1.80
Price/Earnings
-
EPS (TTM)
-4.76
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
514,027
1y Target Est.
83.90
Day's Range
33.70
-
36.25
52 Week's Range
33.70
-
81.13

Historical Summary

Performance
EPS growth
Share Buybacks

About Arvinas Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.arvinas.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
52.87M
Employees
280
Address
5 Science Park, New Haven, CT, United States, 06511
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Latest news

Arvinas Announces Changes to its Board of Directors
Arvinas Announces Changes to its Board of Directors

NEW HAVEN, Conn., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage...
By GlobeNewswire Inc. - 6 weeks ago

Baidu To $180? Plus This Analyst Cuts PT On MacroGenics By 56%
Baidu To $180? Plus This Analyst Cuts PT On MacroGenics By 56%

Mizuho cut the price target on Baidu, Inc. (NASDAQ: BIDU) from $200 to $180. Mizuho...
By Benzinga - 9 weeks ago

Burlington Stores To Surge Over 21%? Plus Wedbush Slashes PT On Jack In The Box
Burlington Stores To Surge Over 21%? Plus Wedbush Slashes PT On Jack In The Box

Barclays raised the price target on Burlington Stores, Inc. (NYSE: BURL) from $164 to $230....
By Benzinga - 9 weeks ago

Analyst Ratings for Arvinas
Analyst Ratings for Arvinas

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish...
By Benzinga - 9 weeks ago

Where Arvinas Stands With Analysts
Where Arvinas Stands With Analysts

Within the last quarter, Arvinas (NASDAQ:ARVN) has observed the following analyst ratings: Bullish Somewhat Bullish...
By Benzinga - 9 weeks ago

Abercrombie & Fitch To Rally 21%? Plus This Analyst Predicts $237 For Autodesk
Abercrombie & Fitch To Rally 21%? Plus This Analyst Predicts $237 For Autodesk

Telsey Advisory Group raised the price target on Abercrombie & Fitch Co. (NYSE: ANF) from...
By Benzinga - 9 weeks ago

Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)

ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2-...
By GlobeNewswire Inc. - 9 weeks ago

Carvana, Crocs And Other Big Losers From Monday
Carvana, Crocs And Other Big Losers From Monday

U.S. stocks closed lower on Monday, with the Nasdaq dropping more than 100 points. Here...
By Benzinga - 9 weeks ago